CA2496211A1 - New purine derivatives, the preparation thereof and their use as pharmaceutical compositions - Google Patents
New purine derivatives, the preparation thereof and their use as pharmaceutical compositions Download PDFInfo
- Publication number
- CA2496211A1 CA2496211A1 CA002496211A CA2496211A CA2496211A1 CA 2496211 A1 CA2496211 A1 CA 2496211A1 CA 002496211 A CA002496211 A CA 002496211A CA 2496211 A CA2496211 A CA 2496211A CA 2496211 A1 CA2496211 A1 CA 2496211A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- amino
- substituted
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title claims abstract description 7
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 229940002612 prodrug Drugs 0.000 claims abstract description 7
- 239000000651 prodrug Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- -1 pyrrolidin-1-ylcarbonyl Chemical group 0.000 claims description 382
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 76
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 125000003277 amino group Chemical group 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000001624 naphthyl group Chemical group 0.000 claims description 26
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 239000011737 fluorine Substances 0.000 claims description 22
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 21
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 21
- 229910052801 chlorine Inorganic materials 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 19
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 16
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 125000002541 furyl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 8
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 150000003212 purines Chemical class 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- KXEVVOQPEOZACT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 KXEVVOQPEOZACT-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 5
- RNRPZHYVLILOGM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-methyl-7-(3-methylbut-2-enyl)-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(C)N(CC=3C4=CC=CC=C4C=CC=3)C(=O)C=2N(CC=C(C)C)C=1N1CCCC(N)C1 RNRPZHYVLILOGM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 4
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- AHRPGBIQGOKCEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-[(4-methoxynaphthalen-1-yl)methyl]-7-(3-methylbut-2-enyl)purin-6-one Chemical compound C12=CC=CC=C2C(OC)=CC=C1CN(C(C=1N2CC=C(C)C)=O)C=NC=1N=C2N1CCCC(N)C1 AHRPGBIQGOKCEJ-UHFFFAOYSA-N 0.000 claims description 3
- KXZCVZCPENDTBZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 KXZCVZCPENDTBZ-UHFFFAOYSA-N 0.000 claims description 3
- ZSJQMFQPGXOVJF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(3-methylbut-2-enyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 ZSJQMFQPGXOVJF-UHFFFAOYSA-N 0.000 claims description 3
- PNOSIUFCRSQTOB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-methylbut-2-enyl)-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=CN(CC=3C4=CC=CC=C4C=CC=3)C(=O)C=2N(CC=C(C)C)C=1N1CCCC(N)C1 PNOSIUFCRSQTOB-UHFFFAOYSA-N 0.000 claims description 3
- UUBYQARNFLJUIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(propan-2-ylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC(C)C)=NC=2N=C1N1CCCC(N)C1 UUBYQARNFLJUIF-UHFFFAOYSA-N 0.000 claims description 3
- LIQQAKDINRZTHI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperidin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCCC3)=NC=2N=C1N1CCCC(N)C1 LIQQAKDINRZTHI-UHFFFAOYSA-N 0.000 claims description 3
- DSUCMFGGJJWNGH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCCC1 DSUCMFGGJJWNGH-UHFFFAOYSA-N 0.000 claims description 3
- JRQQCSZVFBUCTP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCCC1 JRQQCSZVFBUCTP-UHFFFAOYSA-N 0.000 claims description 3
- WRFSHVCQKQZCJT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(F)C=C1 WRFSHVCQKQZCJT-UHFFFAOYSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- MLEOPWDMSPGAJV-UHFFFAOYSA-N 2-amino-8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N)=NC=2N=C1N1CCCC(N)C1 MLEOPWDMSPGAJV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- LNUIDEMUMXLMOV-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-8-(piperidin-4-ylmethyl)-3h-purin-6-one Chemical compound C=1C=C(F)C=CC=1CN1C=2C(O)=NC=NC=2N=C1CC1CCNCC1 LNUIDEMUMXLMOV-UHFFFAOYSA-N 0.000 claims description 2
- VEJJMWUFHYIMLI-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-8-[(1-methylpiperidin-4-yl)methyl]-3h-purin-6-one Chemical compound C1CN(C)CCC1CC(N1CC=2C=CC(F)=CC=2)=NC2=C1C(=O)NC=N2 VEJJMWUFHYIMLI-UHFFFAOYSA-N 0.000 claims description 2
- IHELHBZSOOCKJI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1,2-dimethylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C)=NC=2N=C1N1CCCC(N)C1 IHELHBZSOOCKJI-UHFFFAOYSA-N 0.000 claims description 2
- FWURZHRNHYFNNY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(methylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC)=NC=2N=C1N1CCCC(N)C1 FWURZHRNHYFNNY-UHFFFAOYSA-N 0.000 claims description 2
- KHCNZQNITHNYGN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C=NC=2N=C1N1CCCC(N)C1 KHCNZQNITHNYGN-UHFFFAOYSA-N 0.000 claims description 2
- KYDFKPMXUILEAA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-phenacylpurin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC=CC=1)C=N2 KYDFKPMXUILEAA-UHFFFAOYSA-N 0.000 claims description 2
- MUJRWAFVKMBLQJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(dimethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)C)=NC=2N=C1N1CCCC(N)C1 MUJRWAFVKMBLQJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 claims description 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 16
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims 9
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 claims 2
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- VLBIYRJVPOZOET-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1=CC=CC=C1 VLBIYRJVPOZOET-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 150000007529 inorganic bases Chemical class 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 4
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- 239000000741 silica gel Substances 0.000 description 42
- 229910002027 silica gel Inorganic materials 0.000 description 42
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000013543 active substance Substances 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000001819 mass spectrum Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 14
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- PRSOTPZQRDQXMD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(4-methylpentyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC(C)C)C=1NCC1=CC=CC=C1 PRSOTPZQRDQXMD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GZUSRPVTBVKCCC-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 GZUSRPVTBVKCCC-UHFFFAOYSA-N 0.000 description 2
- RRKJMBVHFCFUKA-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n-ethylacetamide Chemical compound CCNC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 RRKJMBVHFCFUKA-UHFFFAOYSA-N 0.000 description 2
- ZXOHWBJWDQRNQU-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 ZXOHWBJWDQRNQU-UHFFFAOYSA-N 0.000 description 2
- GQJSLRBSMGEGHR-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]acetamide Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)OCC(N)=O)C=N2 GQJSLRBSMGEGHR-UHFFFAOYSA-N 0.000 description 2
- VWXNAPAOLXCYGK-UHFFFAOYSA-N 2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1CCC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 VWXNAPAOLXCYGK-UHFFFAOYSA-N 0.000 description 2
- GTQOPHWORUTDBG-UHFFFAOYSA-N 2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]benzamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1C(N)=O GTQOPHWORUTDBG-UHFFFAOYSA-N 0.000 description 2
- JLNZVAJNRRUVMK-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-1-methyl-6-oxo-2-(2-phenylethyl)purin-7-yl]methyl]benzonitrile Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JLNZVAJNRRUVMK-UHFFFAOYSA-N 0.000 description 2
- ZYHJOGUZHBMFAO-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-6-oxopurin-7-yl]methyl]benzonitrile Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 ZYHJOGUZHBMFAO-UHFFFAOYSA-N 0.000 description 2
- COTHKKBXRJQJNV-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]-n,n-dimethylacetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)N(C)C)=NC=2N=C1N1CCCC(N)C1 COTHKKBXRJQJNV-UHFFFAOYSA-N 0.000 description 2
- MXVVJUKEJMHBOT-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]-n-ethylacetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)NCC)=NC=2N=C1N1CCCC(N)C1 MXVVJUKEJMHBOT-UHFFFAOYSA-N 0.000 description 2
- ZGVPJPKVGYSXHV-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(N)=O)=NC=2N=C1N1CCCC(N)C1 ZGVPJPKVGYSXHV-UHFFFAOYSA-N 0.000 description 2
- IQILBLAIIVGKOY-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(O)=O)=NC=2N=C1N1CCCC(N)C1 IQILBLAIIVGKOY-UHFFFAOYSA-N 0.000 description 2
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
- IZYTVPWMGQQFJU-UHFFFAOYSA-N 3-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]propanenitrile Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCC#N)=NC=2N=C1N1CCCC(N)C1 IZYTVPWMGQQFJU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- WJTIRCVXQBFGHY-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperazin-1-ylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 WJTIRCVXQBFGHY-UHFFFAOYSA-N 0.000 description 2
- KOPVSTAUTXJATB-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperidin-3-ylpurin-6-one Chemical compound N=1C=2N=C(C3CNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 KOPVSTAUTXJATB-UHFFFAOYSA-N 0.000 description 2
- JLIAMELIHQIZQK-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperidin-4-ylpurin-6-one Chemical compound N=1C=2N=C(C3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JLIAMELIHQIZQK-UHFFFAOYSA-N 0.000 description 2
- DPUNDSGILOVWQP-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperazin-1-ylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 DPUNDSGILOVWQP-UHFFFAOYSA-N 0.000 description 2
- XXJGHTUNTCKDEW-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperidin-3-ylpurin-6-one Chemical compound N=1C=2N=C(C3CNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 XXJGHTUNTCKDEW-UHFFFAOYSA-N 0.000 description 2
- FQWIXFCSJOZTTO-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperidin-4-ylpurin-6-one Chemical compound N=1C=2N=C(C3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FQWIXFCSJOZTTO-UHFFFAOYSA-N 0.000 description 2
- OOIHIBBRPDINRI-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-8-(1,4-diazepan-1-yl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OOIHIBBRPDINRI-UHFFFAOYSA-N 0.000 description 2
- NPRVPCMRNIOMMY-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 NPRVPCMRNIOMMY-UHFFFAOYSA-N 0.000 description 2
- KSMIBFQFZLRYPE-UHFFFAOYSA-N 8-(2-aminoethylamino)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(NCCN)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 KSMIBFQFZLRYPE-UHFFFAOYSA-N 0.000 description 2
- HBMJKFUFEOTDEH-UHFFFAOYSA-N 8-(3-aminoazepan-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 HBMJKFUFEOTDEH-UHFFFAOYSA-N 0.000 description 2
- IHBSNILKCZIJNC-UHFFFAOYSA-N 8-(3-aminoazepan-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 IHBSNILKCZIJNC-UHFFFAOYSA-N 0.000 description 2
- NKNQXCRHIIZJQP-UHFFFAOYSA-N 8-(3-aminocyclohexyl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(C3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 NKNQXCRHIIZJQP-UHFFFAOYSA-N 0.000 description 2
- FJTNFYWQTLWDTR-UHFFFAOYSA-N 8-(3-aminocyclohexyl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(C3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FJTNFYWQTLWDTR-UHFFFAOYSA-N 0.000 description 2
- TXZHFHVENMXHTE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3N=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 TXZHFHVENMXHTE-UHFFFAOYSA-N 0.000 description 2
- UMOGJCJKMXWZBE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3SC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 UMOGJCJKMXWZBE-UHFFFAOYSA-N 0.000 description 2
- YGXWTVPUDSMXGJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)(F)F)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 YGXWTVPUDSMXGJ-UHFFFAOYSA-N 0.000 description 2
- YTMDEJDMTYLIHM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(C=CC=3)C(F)(F)F)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 YTMDEJDMTYLIHM-UHFFFAOYSA-N 0.000 description 2
- QRPSFKHJZYEAHB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(naphthalen-1-ylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C4=CC=CC=C4C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 QRPSFKHJZYEAHB-UHFFFAOYSA-N 0.000 description 2
- FLXMKFPTUIVGEM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-[(3-methylphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound CC1=CC=CC(CN2C=3C(=O)N(C)C(CCC=4C=CC=CC=4)=NC=3N=C2N2CC(N)CCC2)=C1 FLXMKFPTUIVGEM-UHFFFAOYSA-N 0.000 description 2
- JOCZHILRODVRIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2,7-dibenzyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC=C1 JOCZHILRODVRIF-UHFFFAOYSA-N 0.000 description 2
- IEPSUMUSBIZHQO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(1,3-benzodioxol-5-ylmethylamino)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C=C4OCOC4=CC=3)=NC=2N=C1N1CCCC(N)C1 IEPSUMUSBIZHQO-UHFFFAOYSA-N 0.000 description 2
- VEXDKNBPWBQESI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C4=CC=CC=C4C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 VEXDKNBPWBQESI-UHFFFAOYSA-N 0.000 description 2
- DMGUQGAHBCENRS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3N=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 DMGUQGAHBCENRS-UHFFFAOYSA-N 0.000 description 2
- HIJIEWCANFRPDA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3SC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 HIJIEWCANFRPDA-UHFFFAOYSA-N 0.000 description 2
- HOKXUPLBAFQSAQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[(3-methylphenyl)methyl]purin-6-one Chemical compound CC1=CC=CC(CN2C=3C(=O)N(C)C(NCC=4C=CC=CC=4)=NC=3N=C2N2CC(N)CCC2)=C1 HOKXUPLBAFQSAQ-UHFFFAOYSA-N 0.000 description 2
- LEISEQWHMSDMMB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)(F)F)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 LEISEQWHMSDMMB-UHFFFAOYSA-N 0.000 description 2
- GRJASLTVWZSWOS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(C=CC=3)C(F)(F)F)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 GRJASLTVWZSWOS-UHFFFAOYSA-N 0.000 description 2
- GIEDBTBRUJHKQZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(2,3-dimethylbut-2-enyl)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC(C)=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 GIEDBTBRUJHKQZ-UHFFFAOYSA-N 0.000 description 2
- FTXNKGLVTOYRPO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3-chloro-4,4,4-trifluorobut-2-enyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)C(F)(F)F)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FTXNKGLVTOYRPO-UHFFFAOYSA-N 0.000 description 2
- MNLNTHIRGONVJU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3-chloroprop-2-enyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=CCl)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 MNLNTHIRGONVJU-UHFFFAOYSA-N 0.000 description 2
- VUHZUUQLBBSMSE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclohexen-1-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCCC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 VUHZUUQLBBSMSE-UHFFFAOYSA-N 0.000 description 2
- ILFVBNGBYJQYDV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclohexylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC3CCCCC3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 ILFVBNGBYJQYDV-UHFFFAOYSA-N 0.000 description 2
- RATUKNHJSYAEHE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclopenten-1-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 RATUKNHJSYAEHE-UHFFFAOYSA-N 0.000 description 2
- RGNZFJLRSHXDNM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(furan-2-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3OC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 RGNZFJLRSHXDNM-UHFFFAOYSA-N 0.000 description 2
- OYPXHQZMQLREQH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(2-chlorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)Cl)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OYPXHQZMQLREQH-UHFFFAOYSA-N 0.000 description 2
- SHWXAEPYBCGDOZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(2-methoxyphenyl)methyl]-1-methylpurin-6-one Chemical compound COC1=CC=CC=C1CN1C(C(=O)N(C)C(NCC=2C=CC=CC=2)=N2)=C2N=C1N1CC(N)CCC1 SHWXAEPYBCGDOZ-UHFFFAOYSA-N 0.000 description 2
- JEZDREHKVMZBOZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(3,4-difluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(F)C(F)=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 JEZDREHKVMZBOZ-UHFFFAOYSA-N 0.000 description 2
- OJDIRPFGMHQCCE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(3-bromophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(Br)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OJDIRPFGMHQCCE-UHFFFAOYSA-N 0.000 description 2
- OXUNPAXYXYVVRS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(4-fluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC(F)=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OXUNPAXYXYVVRS-UHFFFAOYSA-N 0.000 description 2
- BYGDUKIAVIQCLN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[[3-(difluoromethoxy)phenyl]methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)F)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 BYGDUKIAVIQCLN-UHFFFAOYSA-N 0.000 description 2
- KQKPBMRCKYGONU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-but-2-enyl-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=CC)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 KQKPBMRCKYGONU-UHFFFAOYSA-N 0.000 description 2
- NAAJUEREAPVOPX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-but-2-ynyl-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 NAAJUEREAPVOPX-UHFFFAOYSA-N 0.000 description 2
- RTDVHLKINWMRDM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-anilino-7-benzyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1=CC=CC=C1 RTDVHLKINWMRDM-UHFFFAOYSA-N 0.000 description 2
- AEJXFOVWNYZJTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3,3-dichloroprop-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)Cl)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 AEJXFOVWNYZJTO-UHFFFAOYSA-N 0.000 description 2
- JGJLGBRWFGKITQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-chloro-4,4,4-trifluorobut-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)C(F)(F)F)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JGJLGBRWFGKITQ-UHFFFAOYSA-N 0.000 description 2
- ZBMHASDARSEIEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-chlorobut-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(Cl)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 ZBMHASDARSEIEJ-UHFFFAOYSA-N 0.000 description 2
- MCDXBUAVIDDABU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-chloroprop-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=CCl)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 MCDXBUAVIDDABU-UHFFFAOYSA-N 0.000 description 2
- LMRUTLWDURUNSL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(cyclohexen-1-ylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCCC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 LMRUTLWDURUNSL-UHFFFAOYSA-N 0.000 description 2
- PPKDYANCRFNQLP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(cyclohexylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC3CCCCC3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 PPKDYANCRFNQLP-UHFFFAOYSA-N 0.000 description 2
- SZNGHRDJOPIBRB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(furan-2-ylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3OC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 SZNGHRDJOPIBRB-UHFFFAOYSA-N 0.000 description 2
- ZSNKHTXXIPWMSN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(2-chlorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)Cl)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 ZSNKHTXXIPWMSN-UHFFFAOYSA-N 0.000 description 2
- CDZDXRRTYLANGN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(2-methoxyphenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound COC1=CC=CC=C1CN1C(C(=O)N(C)C(CCC=2C=CC=CC=2)=N2)=C2N=C1N1CC(N)CCC1 CDZDXRRTYLANGN-UHFFFAOYSA-N 0.000 description 2
- QJCNFDMECJZPQU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(3,4-difluorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(F)C(F)=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 QJCNFDMECJZPQU-UHFFFAOYSA-N 0.000 description 2
- BRGKDZMBIKRQGZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(3-bromophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(Br)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 BRGKDZMBIKRQGZ-UHFFFAOYSA-N 0.000 description 2
- FZDZRZNQLRLCGL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(4-fluorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC(F)=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 FZDZRZNQLRLCGL-UHFFFAOYSA-N 0.000 description 2
- AJDXZDFFHUPNRJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[[3-(difluoromethoxy)phenyl]methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)F)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 AJDXZDFFHUPNRJ-UHFFFAOYSA-N 0.000 description 2
- GBXWXNIENFNLHA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-methylpropyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(C)C)C=1CCC1=CC=CC=C1 GBXWXNIENFNLHA-UHFFFAOYSA-N 0.000 description 2
- TXAFAUAMLDZBPT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CCC=1C=CC=CC=1)C=N2 TXAFAUAMLDZBPT-UHFFFAOYSA-N 0.000 description 2
- IGSBBMGEAKIJLD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=C(C)C)C=1CCC1=CC=CC=C1 IGSBBMGEAKIJLD-UHFFFAOYSA-N 0.000 description 2
- SPEZDYJTUIHHLM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(4-methylpentyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC(C)C)C=1CCC1=CC=CC=C1 SPEZDYJTUIHHLM-UHFFFAOYSA-N 0.000 description 2
- VRQIZTXSIXLEFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(cyclohexylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CCCCC1)C(CCC=1C=CC=CC=1)=N2 VRQIZTXSIXLEFG-UHFFFAOYSA-N 0.000 description 2
- SIZOCPXUQDDGME-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(cyclopropylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CC1)C(CCC=1C=CC=CC=1)=N2 SIZOCPXUQDDGME-UHFFFAOYSA-N 0.000 description 2
- UJDIFSBOEVETBY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(isoquinolin-1-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3C=CN=1)C=N2 UJDIFSBOEVETBY-UHFFFAOYSA-N 0.000 description 2
- XHEXWCPZUQQYAC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3C=CC=1)C=N2 XHEXWCPZUQQYAC-UHFFFAOYSA-N 0.000 description 2
- MKXYBQRQWVZKQG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(pyrazin-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1N=CC=NC=1)C=N2 MKXYBQRQWVZKQG-UHFFFAOYSA-N 0.000 description 2
- BVNRDSCVCJZEEC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinazolin-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1N=C3C=CC=CC3=CN=1)C=N2 BVNRDSCVCJZEEC-UHFFFAOYSA-N 0.000 description 2
- SRGFGVSVZBINKL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinazolin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3N=CN=1)C=N2 SRGFGVSVZBINKL-UHFFFAOYSA-N 0.000 description 2
- UNHHZHHPZZSDIK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinolin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3N=CC=1)C=N2 UNHHZHHPZZSDIK-UHFFFAOYSA-N 0.000 description 2
- FPDPCTGIJZVRQT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(2-fluorophenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C(=CC=CC=1)F)C(CCC=1C=CC=CC=1)=N2 FPDPCTGIJZVRQT-UHFFFAOYSA-N 0.000 description 2
- RLGUDMXAXARJKV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]purin-6-one Chemical compound O1C(C)=C(C)N=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 RLGUDMXAXARJKV-UHFFFAOYSA-N 0.000 description 2
- MBPAPQYAAGESDI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,5-dimethyl-1,3-thiazol-2-yl)methyl]purin-6-one Chemical compound S1C(C)=C(C)N=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 MBPAPQYAAGESDI-UHFFFAOYSA-N 0.000 description 2
- GPYXEEGZNNSMLJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,6-dimethylpyrimidin-2-yl)methyl]purin-6-one Chemical compound CC1=CC(C)=NC(CN2C(C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=C2)=O)=N1 GPYXEEGZNNSMLJ-UHFFFAOYSA-N 0.000 description 2
- SOUYYRGBWZUUBE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4-chlorophenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CC(Cl)=CC=1)C(CCC=1C=CC=CC=1)=N2 SOUYYRGBWZUUBE-UHFFFAOYSA-N 0.000 description 2
- QYEKCIPKOXQVCY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4-methylphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 QYEKCIPKOXQVCY-UHFFFAOYSA-N 0.000 description 2
- ILJMYOFXRFXNOX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(2-hydroxyphenyl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)O)C=N2 ILJMYOFXRFXNOX-UHFFFAOYSA-N 0.000 description 2
- XNCMOYRGJVCLBO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(2-methoxyphenyl)-2-oxoethyl]purin-6-one Chemical compound COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 XNCMOYRGJVCLBO-UHFFFAOYSA-N 0.000 description 2
- JHSKTCXSAZOOQN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-butyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC)C=1CCC1=CC=CC=C1 JHSKTCXSAZOOQN-UHFFFAOYSA-N 0.000 description 2
- FCRGCPJOWAVWGJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-ethyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC)C=1CCC1=CC=CC=C1 FCRGCPJOWAVWGJ-UHFFFAOYSA-N 0.000 description 2
- HXPLOJURYFYFKC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-hexyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCCC)C=1CCC1=CC=CC=C1 HXPLOJURYFYFKC-UHFFFAOYSA-N 0.000 description 2
- JVSISJSQEOCVCW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-methylpropyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC(C)C)=NC=2N=C1N1CCCC(N)C1 JVSISJSQEOCVCW-UHFFFAOYSA-N 0.000 description 2
- DJWYGSCVGNTGIK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-methylsulfanylethylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCSC)=NC=2N=C1N1CCCC(N)C1 DJWYGSCVGNTGIK-UHFFFAOYSA-N 0.000 description 2
- ZMTXMYOOTIGTSG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethenyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC=C1 ZMTXMYOOTIGTSG-UHFFFAOYSA-N 0.000 description 2
- JZQVRWYARMXWGI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JZQVRWYARMXWGI-UHFFFAOYSA-N 0.000 description 2
- RSJCCIOBKLLLAH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylsulfanylethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCSC1=CC=CC=C1 RSJCCIOBKLLLAH-UHFFFAOYSA-N 0.000 description 2
- ASWYCMYQPGFJLG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-pyridin-2-ylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=N1 ASWYCMYQPGFJLG-UHFFFAOYSA-N 0.000 description 2
- MDTWTTKMZFPJHM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-methylbut-2-enyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC=C(C)C)=NC=2N=C1N1CCCC(N)C1 MDTWTTKMZFPJHM-UHFFFAOYSA-N 0.000 description 2
- FBONEQBOEFBZJV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-methylbutyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCC(C)C)=NC=2N=C1N1CCCC(N)C1 FBONEQBOEFBZJV-UHFFFAOYSA-N 0.000 description 2
- OCWOILMUCVOHSK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-phenylprop-2-enyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC=CC1=CC=CC=C1 OCWOILMUCVOHSK-UHFFFAOYSA-N 0.000 description 2
- CEQSSXVDDQUNKO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-phenylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CC=C1 CEQSSXVDDQUNKO-UHFFFAOYSA-N 0.000 description 2
- MDDSYLBWGMLYND-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-pyridin-2-ylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CC=N1 MDDSYLBWGMLYND-UHFFFAOYSA-N 0.000 description 2
- ZFKSENLRTKJDEK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(4-methylpentyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC(C)C)=NC=2N=C1N1CCCC(N)C1 ZFKSENLRTKJDEK-UHFFFAOYSA-N 0.000 description 2
- QNUKTZCGLRQPQK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(naphthalen-1-ylmethylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C4=CC=CC=C4C=CC=3)=NC=2N=C1N1CCCC(N)C1 QNUKTZCGLRQPQK-UHFFFAOYSA-N 0.000 description 2
- IYSMLVQVYUVGEQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC=N1 IYSMLVQVYUVGEQ-UHFFFAOYSA-N 0.000 description 2
- OBOSNOJEUHTKIO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyridin-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=N1 OBOSNOJEUHTKIO-UHFFFAOYSA-N 0.000 description 2
- OVFHJWDUJLGQTG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CS1 OVFHJWDUJLGQTG-UHFFFAOYSA-N 0.000 description 2
- DWEMHQBFFXMEIW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(thiophen-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CS1 DWEMHQBFFXMEIW-UHFFFAOYSA-N 0.000 description 2
- GKEOPLDMIJUMSI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-morpholin-4-yl-2-oxoethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCOCC1 GKEOPLDMIJUMSI-UHFFFAOYSA-N 0.000 description 2
- LBTMRLXPZGRVFH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-oxo-2-piperidin-1-ylethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCCCC1 LBTMRLXPZGRVFH-UHFFFAOYSA-N 0.000 description 2
- GRWRTUHZDJKGKK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-oxo-2-pyrrolidin-1-ylethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCCC1 GRWRTUHZDJKGKK-UHFFFAOYSA-N 0.000 description 2
- SXPWDGACCWKZOG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(3-methyl-1,2-oxazol-5-yl)methylamino]purin-6-one Chemical compound O1N=C(C)C=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 SXPWDGACCWKZOG-UHFFFAOYSA-N 0.000 description 2
- YUWVUCXSMKDFNT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(4-methyl-1,3-thiazol-2-yl)methylamino]purin-6-one Chemical compound CC1=CSC(CNC=2N(C(=O)C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=2)C)=N1 YUWVUCXSMKDFNT-UHFFFAOYSA-N 0.000 description 2
- NIQJJUNNUKXPIO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(4-methylphenyl)methylamino]purin-6-one Chemical compound C1=CC(C)=CC=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 NIQJJUNNUKXPIO-UHFFFAOYSA-N 0.000 description 2
- QYTODSPMGZSARF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(2-methylsulfonylphenyl)ethyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1S(C)(=O)=O QYTODSPMGZSARF-UHFFFAOYSA-N 0.000 description 2
- WBQMLBZEKCBWFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(4-methylphenyl)ethenyl]purin-6-one Chemical compound C1=CC(C)=CC=C1C=CC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 WBQMLBZEKCBWFG-UHFFFAOYSA-N 0.000 description 2
- AYURKCBVGIPMIE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(4-methylphenyl)ethyl]purin-6-one Chemical compound C1=CC(C)=CC=C1CCC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 AYURKCBVGIPMIE-UHFFFAOYSA-N 0.000 description 2
- ZXNGPBYBGLBPRG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(methylamino)ethylamino]purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC)=NC=2N=C1N1CCCC(N)C1 ZXNGPBYBGLBPRG-UHFFFAOYSA-N 0.000 description 2
- VTHAQAUKOCDLPD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethoxy)phenyl]ethenyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(OC(F)(F)F)=C1 VTHAQAUKOCDLPD-UHFFFAOYSA-N 0.000 description 2
- KEBHFUUMRDDGDG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethyl)phenyl]ethenyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(C(F)(F)F)=C1 KEBHFUUMRDDGDG-UHFFFAOYSA-N 0.000 description 2
- FYISYIRHAGIPNW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethyl)phenyl]ethyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC(C(F)(F)F)=C1 FYISYIRHAGIPNW-UHFFFAOYSA-N 0.000 description 2
- OEUZBGKFPZNBIX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(OC(F)(F)F)=C1 OEUZBGKFPZNBIX-UHFFFAOYSA-N 0.000 description 2
- YVSDXPPKCZWPSV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(C(F)(F)F)=C1 YVSDXPPKCZWPSV-UHFFFAOYSA-N 0.000 description 2
- YYNMAJXFQCJXCR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[4-(trifluoromethoxy)phenyl]methylamino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(OC(F)(F)F)C=C1 YYNMAJXFQCJXCR-UHFFFAOYSA-N 0.000 description 2
- RBFIISQFJLBWKW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(C(F)(F)F)C=C1 RBFIISQFJLBWKW-UHFFFAOYSA-N 0.000 description 2
- FOKXYDANFVFWBF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-morpholin-4-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCOCC3)=NC=2N=C1N1CCCC(N)C1 FOKXYDANFVFWBF-UHFFFAOYSA-N 0.000 description 2
- RBLLCLSIQVHQPY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pent-4-enylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC=C)=NC=2N=C1N1CCCC(N)C1 RBLLCLSIQVHQPY-UHFFFAOYSA-N 0.000 description 2
- IXCOLSCXKFTMDE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pentylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCC)=NC=2N=C1N1CCCC(N)C1 IXCOLSCXKFTMDE-UHFFFAOYSA-N 0.000 description 2
- KGLQLNZJUAYWPY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-phenylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3C=CC=CC=3)=NC=2N=C1N1CCCC(N)C1 KGLQLNZJUAYWPY-UHFFFAOYSA-N 0.000 description 2
- ARKIRKYLMOEVBY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperazin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCNCC3)=NC=2N=C1N1CCCC(N)C1 ARKIRKYLMOEVBY-UHFFFAOYSA-N 0.000 description 2
- ZAUSEAWVDDKTJP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-prop-2-ynylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC#C)=NC=2N=C1N1CCCC(N)C1 ZAUSEAWVDDKTJP-UHFFFAOYSA-N 0.000 description 2
- VYBXZISXBSNGEH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-propan-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C(C)C)=NC=2N=C1N1CCCC(N)C1 VYBXZISXBSNGEH-UHFFFAOYSA-N 0.000 description 2
- CBAYPUCIPGLMMY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-propylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCC)=NC=2N=C1N1CCCC(N)C1 CBAYPUCIPGLMMY-UHFFFAOYSA-N 0.000 description 2
- UCPAQYHYWJHZSE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyridin-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3N=CC=CC=3)=NC=2N=C1N1CCCC(N)C1 UCPAQYHYWJHZSE-UHFFFAOYSA-N 0.000 description 2
- YLXMCLJUUVRELY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyridin-4-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3C=CN=CC=3)=NC=2N=C1N1CCCC(N)C1 YLXMCLJUUVRELY-UHFFFAOYSA-N 0.000 description 2
- KHWOHEHMYBJPCE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyrrolidin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCC3)=NC=2N=C1N1CCCC(N)C1 KHWOHEHMYBJPCE-UHFFFAOYSA-N 0.000 description 2
- FDMXWZIGALXUOM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-thiophen-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3SC=CC=3)=NC=2N=C1N1CCCC(N)C1 FDMXWZIGALXUOM-UHFFFAOYSA-N 0.000 description 2
- CCZIWTGXULXPIG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-pentyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCC)C=1CCC1=CC=CC=C1 CCZIWTGXULXPIG-UHFFFAOYSA-N 0.000 description 2
- VGBGNGBUZIEHCC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-cyclohexylethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1CCCCC1 VGBGNGBUZIEHCC-UHFFFAOYSA-N 0.000 description 2
- JGUCKNXCXKVYIL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-propan-2-ylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C(C)C)C=1CCC1=CC=CC=C1 JGUCKNXCXKVYIL-UHFFFAOYSA-N 0.000 description 2
- OTOANSFVEYBSPD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-propylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C=1CCC1=CC=CC=C1 OTOANSFVEYBSPD-UHFFFAOYSA-N 0.000 description 2
- XRSVWEKWQHETJC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-cyclohexyl-2-oxoethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C1CCCCC1)C(NCC=1C=CC=CC=1)=N2 XRSVWEKWQHETJC-UHFFFAOYSA-N 0.000 description 2
- BEQCUZYRQKHANP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-methylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(C)C)C=1NCC1=CC=CC=C1 BEQCUZYRQKHANP-UHFFFAOYSA-N 0.000 description 2
- ARPWTWBFTBESEM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxo-2-pyridin-3-ylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=NC=CC=1)C(NCC=1C=CC=CC=1)=N2 ARPWTWBFTBESEM-UHFFFAOYSA-N 0.000 description 2
- CSRMUTJKUKNHTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxo-2-thiophen-2-ylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1SC=CC=1)C(NCC=1C=CC=CC=1)=N2 CSRMUTJKUKNHTO-UHFFFAOYSA-N 0.000 description 2
- JIJNOXBMFZYGTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxopropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(=O)C)C=1NCC1=CC=CC=C1 JIJNOXBMFZYGTO-UHFFFAOYSA-N 0.000 description 2
- ASXXPCAZXRTSEU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(cyclohexylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CCCCC1)C(NCC=1C=CC=CC=1)=N2 ASXXPCAZXRTSEU-UHFFFAOYSA-N 0.000 description 2
- VBXCIKRPLUZUEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(furan-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1OC=CC=1)C(NCC=1C=CC=CC=1)=N2 VBXCIKRPLUZUEJ-UHFFFAOYSA-N 0.000 description 2
- GXNHXSBRFKPJAQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(pyridin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CN=CC=1)C(NCC=1C=CC=CC=1)=N2 GXNHXSBRFKPJAQ-UHFFFAOYSA-N 0.000 description 2
- NIFZCVWFNVTROB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(thiophen-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1SC=CC=1)C(NCC=1C=CC=CC=1)=N2 NIFZCVWFNVTROB-UHFFFAOYSA-N 0.000 description 2
- OXJAWLNSOZOBPU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(2,4-dimethoxyphenyl)methyl]purin-6-one Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 OXJAWLNSOZOBPU-UHFFFAOYSA-N 0.000 description 2
- RLBLLUJMKRKDFI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(2,4-dimethylphenyl)methyl]purin-6-one Chemical compound CC1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 RLBLLUJMKRKDFI-UHFFFAOYSA-N 0.000 description 2
- PNZWJAOYRZEADH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(3-methyl-1,2-oxazol-5-yl)methyl]purin-6-one Chemical compound O1N=C(C)C=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 PNZWJAOYRZEADH-UHFFFAOYSA-N 0.000 description 2
- WZELSLVZRDFEDD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(4-chlorophenyl)methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CC(Cl)=CC=1)C(NCC=1C=CC=CC=1)=N2 WZELSLVZRDFEDD-UHFFFAOYSA-N 0.000 description 2
- QWIAOYMGHWMLBJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(4-methylphenyl)methyl]purin-6-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 QWIAOYMGHWMLBJ-UHFFFAOYSA-N 0.000 description 2
- JDSDXBOWAXMCIR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(2,4-dichlorophenyl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC(Cl)=CC=1)Cl)C(NCC=1C=CC=CC=1)=N2 JDSDXBOWAXMCIR-UHFFFAOYSA-N 0.000 description 2
- CXDULZDQSPGGDZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(4-methoxyphenyl)-2-oxoethyl]purin-6-one Chemical compound C1=CC(OC)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 CXDULZDQSPGGDZ-UHFFFAOYSA-N 0.000 description 2
- YYYQOYZYSNETDO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(4-methylphenyl)-2-oxoethyl]purin-6-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 YYYQOYZYSNETDO-UHFFFAOYSA-N 0.000 description 2
- SEOFULGWOOEQKD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(furan-2-yl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1OC=CC=1)C(NCC=1C=CC=CC=1)=N2 SEOFULGWOOEQKD-UHFFFAOYSA-N 0.000 description 2
- PEJMQYYSHJMTCL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-[4-(difluoromethoxy)phenyl]-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)F)=CC=1)C(NCC=1C=CC=CC=1)=N2 PEJMQYYSHJMTCL-UHFFFAOYSA-N 0.000 description 2
- UKNUBAIFRJMNCF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)(F)F)=CC=1)C(NCC=1C=CC=CC=1)=N2 UKNUBAIFRJMNCF-UHFFFAOYSA-N 0.000 description 2
- NLSQFLWEFVTZKJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(=CC=1)C(F)(F)F)C(NCC=1C=CC=CC=1)=N2 NLSQFLWEFVTZKJ-UHFFFAOYSA-N 0.000 description 2
- AASCIABTPSKJIE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[[3-(difluoromethoxy)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(OC(F)F)C=CC=1)C(NCC=1C=CC=CC=1)=N2 AASCIABTPSKJIE-UHFFFAOYSA-N 0.000 description 2
- IIWKWNGZUAZNQM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(C=CC=1)C(F)(F)F)C(NCC=1C=CC=CC=1)=N2 IIWKWNGZUAZNQM-UHFFFAOYSA-N 0.000 description 2
- AFIKIBGUWPTEKP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-propan-2-ylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C(C)C)C=1NCC1=CC=CC=C1 AFIKIBGUWPTEKP-UHFFFAOYSA-N 0.000 description 2
- MQMCATIZRSOLPC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclobutylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCC1 MQMCATIZRSOLPC-UHFFFAOYSA-N 0.000 description 2
- SZFPMAWWDKIRRT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1CCCCC1 SZFPMAWWDKIRRT-UHFFFAOYSA-N 0.000 description 2
- IVYNXBUBDULVCG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopentylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCC1 IVYNXBUBDULVCG-UHFFFAOYSA-N 0.000 description 2
- XSFPYYYLCAIBPG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopentylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1CCCC1 XSFPYYYLCAIBPG-UHFFFAOYSA-N 0.000 description 2
- DFVLBFNFVHNKNA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-yl)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3OC=CC=3)=NC=2N=C1N1CCCC(N)C1 DFVLBFNFVHNKNA-UHFFFAOYSA-N 0.000 description 2
- FSWAORDNQRYVHS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CO1 FSWAORDNQRYVHS-UHFFFAOYSA-N 0.000 description 2
- JIBONTLFMNFVDB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-ylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CO1 JIBONTLFMNFVDB-UHFFFAOYSA-N 0.000 description 2
- GZTVCCYTFWUEHV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(isoquinolin-1-ylmethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C4=CC=CC=C4C=CN=3)=NC=2N=C1N1CCCC(N)C1 GZTVCCYTFWUEHV-UHFFFAOYSA-N 0.000 description 2
- YSJDNHTUASPRJU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3,4-dichlorophenyl)methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(Cl)C(Cl)=C1 YSJDNHTUASPRJU-UHFFFAOYSA-N 0.000 description 2
- KWMVZWFBEVEENG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-bromophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(Br)=C1 KWMVZWFBEVEENG-UHFFFAOYSA-N 0.000 description 2
- JJWWGJJVWCHXES-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-chlorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(Cl)=C1 JJWWGJJVWCHXES-UHFFFAOYSA-N 0.000 description 2
- UWBSEEKRBHJVEH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-methoxyphenyl)methyl]-1-methylpurin-6-one Chemical compound COC1=CC=CC(CC=2N(C(=O)C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=2)C)=C1 UWBSEEKRBHJVEH-UHFFFAOYSA-N 0.000 description 2
- KBPPOWJLRLRGKY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4,5-dimethyl-1,3-oxazol-2-yl)methylamino]-1-methylpurin-6-one Chemical compound O1C(C)=C(C)N=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 KBPPOWJLRLRGKY-UHFFFAOYSA-N 0.000 description 2
- UNQKNYKMOFDSDV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=C(F)C=C1 UNQKNYKMOFDSDV-UHFFFAOYSA-N 0.000 description 2
- YKNKQJATMBNEBH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-methoxyphenyl)methylamino]-1-methylpurin-6-one Chemical compound C1=CC(OC)=CC=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 YKNKQJATMBNEBH-UHFFFAOYSA-N 0.000 description 2
- DNPWFFCLVWFUJL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(2-chlorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC=C1Cl DNPWFFCLVWFUJL-UHFFFAOYSA-N 0.000 description 2
- LNFILCMEQZJNPS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(2-fluorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1F LNFILCMEQZJNPS-UHFFFAOYSA-N 0.000 description 2
- HRCMCAZOTHKPGS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3,4-dimethoxyphenyl)ethenyl]-1-methylpurin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 HRCMCAZOTHKPGS-UHFFFAOYSA-N 0.000 description 2
- RTGKPSZLHNTBHY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-chlorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(Cl)=C1 RTGKPSZLHNTBHY-UHFFFAOYSA-N 0.000 description 2
- YOIKQMWUGNKVRV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-chlorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC(Cl)=C1 YOIKQMWUGNKVRV-UHFFFAOYSA-N 0.000 description 2
- XJVCQLAUQKBJRX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-fluorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(F)=C1 XJVCQLAUQKBJRX-UHFFFAOYSA-N 0.000 description 2
- YOKWHIGQYYTNJF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(4-fluorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=C(F)C=C1 YOKWHIGQYYTNJF-UHFFFAOYSA-N 0.000 description 2
- MCUCPUKTSXQEQL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(furan-2-yl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CO1 MCUCPUKTSXQEQL-UHFFFAOYSA-N 0.000 description 2
- XAFOOIBQIKMFKF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[3-(dimethylamino)propylamino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCCN(C)C)=NC=2N=C1N1CCCC(N)C1 XAFOOIBQIKMFKF-UHFFFAOYSA-N 0.000 description 2
- KJIHABVKCFKCTR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[3-(furan-2-yl)propyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CO1 KJIHABVKCFKCTR-UHFFFAOYSA-N 0.000 description 2
- ZHSKBZCJGINKHI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[[4-(difluoromethoxy)phenyl]methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(OC(F)F)C=C1 ZHSKBZCJGINKHI-UHFFFAOYSA-N 0.000 description 2
- NYFBBLZNGYQCAE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-butyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC)=NC=2N=C1N1CCCC(N)C1 NYFBBLZNGYQCAE-UHFFFAOYSA-N 0.000 description 2
- GJRLQXVOPDYYJI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-cyclohexyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C3CCCCC3)=NC=2N=C1N1CCCC(N)C1 GJRLQXVOPDYYJI-UHFFFAOYSA-N 0.000 description 2
- FTKQPIQQXHKWEG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-cyclopentyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C3CCCC3)=NC=2N=C1N1CCCC(N)C1 FTKQPIQQXHKWEG-UHFFFAOYSA-N 0.000 description 2
- OTNUTFMNMNJFPJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-ethyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC)=NC=2N=C1N1CCCC(N)C1 OTNUTFMNMNJFPJ-UHFFFAOYSA-N 0.000 description 2
- DGAUHGLZDHQOAT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-hex-5-enyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCC=C)=NC=2N=C1N1CCCC(N)C1 DGAUHGLZDHQOAT-UHFFFAOYSA-N 0.000 description 2
- DMSLPMPVUZBCFM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-hexyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCCC)=NC=2N=C1N1CCCC(N)C1 DMSLPMPVUZBCFM-UHFFFAOYSA-N 0.000 description 2
- NRHCAFORTDHCLF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 NRHCAFORTDHCLF-UHFFFAOYSA-N 0.000 description 2
- POPGOKSVSIXPFN-UHFFFAOYSA-N 8-(3-aminopyrrolidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 POPGOKSVSIXPFN-UHFFFAOYSA-N 0.000 description 2
- GWFFCDILFMQZQV-UHFFFAOYSA-N 8-(3-aminopyrrolidin-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 GWFFCDILFMQZQV-UHFFFAOYSA-N 0.000 description 2
- UMDOHRAMLXMCHJ-UHFFFAOYSA-N 8-(4-aminoazepan-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CCC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 UMDOHRAMLXMCHJ-UHFFFAOYSA-N 0.000 description 2
- HGXKPNSBDPVZOS-UHFFFAOYSA-N 8-[(2-aminocyclohexyl)amino]-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(NC3C(CCCC3)N)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 HGXKPNSBDPVZOS-UHFFFAOYSA-N 0.000 description 2
- QNGNFOLXDVRAMB-UHFFFAOYSA-N 8-[(2-aminocyclohexyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(NC3C(CCCC3)N)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 QNGNFOLXDVRAMB-UHFFFAOYSA-N 0.000 description 2
- JGNHKCGUBNXEOU-UHFFFAOYSA-N 8-[2-aminoethyl(ethyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=3C=CC=CC=3)C(N(CCN)CC)=NC=2N=C1NCC1=CC=CC=C1 JGNHKCGUBNXEOU-UHFFFAOYSA-N 0.000 description 2
- WSQGDCFBADLRKX-UHFFFAOYSA-N 8-[2-aminoethyl(methyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=3C=CC=CC=3)C(N(CCN)C)=NC=2N=C1NCC1=CC=CC=C1 WSQGDCFBADLRKX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- AFDCLFJBXACOQE-UHFFFAOYSA-N ethyl 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 AFDCLFJBXACOQE-UHFFFAOYSA-N 0.000 description 2
- PPKCNVQNYROZBN-UHFFFAOYSA-N ethyl 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetate Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)OCC)=NC=2N=C1N1CCCC(N)C1 PPKCNVQNYROZBN-UHFFFAOYSA-N 0.000 description 2
- QRPCEFJWXVWWHQ-UHFFFAOYSA-N ethyl n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]carbamate Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC(=O)OCC)=NC=2N=C1N1CCCC(N)C1 QRPCEFJWXVWWHQ-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000002660 insulin-secreting cell Anatomy 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- XNRUFCCSINPRKO-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1NS(C)(=O)=O XNRUFCCSINPRKO-UHFFFAOYSA-N 0.000 description 2
- FCELOWHWFAVYDH-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 FCELOWHWFAVYDH-UHFFFAOYSA-N 0.000 description 2
- QFJDXSJIENIQSB-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]acetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC(=O)C)=NC=2N=C1N1CCCC(N)C1 QFJDXSJIENIQSB-UHFFFAOYSA-N 0.000 description 2
- XHFVDPSNHQGBFL-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]benzamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCNC(=O)C1=CC=CC=C1 XHFVDPSNHQGBFL-UHFFFAOYSA-N 0.000 description 2
- UWUFKRPWUNRNOG-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]benzenesulfonamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCNS(=O)(=O)C1=CC=CC=C1 UWUFKRPWUNRNOG-UHFFFAOYSA-N 0.000 description 2
- IBHZULCOLBZDGC-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]methanesulfonamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNS(C)(=O)=O)=NC=2N=C1N1CCCC(N)C1 IBHZULCOLBZDGC-UHFFFAOYSA-N 0.000 description 2
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical group 0.000 description 2
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- IVBVTJRJXOWINB-UHFFFAOYSA-N (4-methoxynaphthalen-1-yl)methanamine Chemical compound C1=CC=C2C(OC)=CC=C(CN)C2=C1 IVBVTJRJXOWINB-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- FLAJOCQODOSXOM-UHFFFAOYSA-N 1-[2-(2-aminophenyl)-2-oxoethyl]-8-(3-aminopiperidin-1-yl)-7-benzylpurin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)N)C=N2 FLAJOCQODOSXOM-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LNSCNEJNLACZPA-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(2-methylphenyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=CC=C1C LNSCNEJNLACZPA-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- MYRFQYMNEHTQDJ-UHFFFAOYSA-N 2-amino-8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N)=NC=2N=C1N1CCCC(N)C1 MYRFQYMNEHTQDJ-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- MKYVZONQQIQRRI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1,7-dibenzyl-2-methylsulfanylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CC=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 MKYVZONQQIQRRI-UHFFFAOYSA-N 0.000 description 1
- UFPRKXYSXDXGAL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-benzyl-2-methyl-7-(3-methylbut-2-enyl)purin-6-one Chemical compound O=C1C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C(C)N1CC1=CC=CC=C1 UFPRKXYSXDXGAL-UHFFFAOYSA-N 0.000 description 1
- OZQBTWNPJJPWAA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 OZQBTWNPJJPWAA-UHFFFAOYSA-N 0.000 description 1
- BAQZTNVCGOQKAB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(3-methylbut-2-enyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 BAQZTNVCGOQKAB-UHFFFAOYSA-N 0.000 description 1
- ZOYFLQQOAHGFQF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1,2-dimethylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C)=NC=2N=C1N1CCCC(N)C1 ZOYFLQQOAHGFQF-UHFFFAOYSA-N 0.000 description 1
- QRRGLABMPXVARK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1=CC=CC=C1 QRRGLABMPXVARK-UHFFFAOYSA-N 0.000 description 1
- WHCXDZPBBIMTDS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(methylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC)=NC=2N=C1N1CCCC(N)C1 WHCXDZPBBIMTDS-UHFFFAOYSA-N 0.000 description 1
- YXQNPRVALZMWSB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(propan-2-ylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC(C)C)=NC=2N=C1N1CCCC(N)C1 YXQNPRVALZMWSB-UHFFFAOYSA-N 0.000 description 1
- YEGFHDBFTNGPTC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyrazin-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CN=CC=N1 YEGFHDBFTNGPTC-UHFFFAOYSA-N 0.000 description 1
- SHTXEPKRVLXELJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-methylsulfanylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(SC)=NC=2N=C1N1CCCC(N)C1 SHTXEPKRVLXELJ-UHFFFAOYSA-N 0.000 description 1
- HLANVPMVMPQUHW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperidin-1-ylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCCC3)=NC=2N=C1N1CCCC(N)C1 HLANVPMVMPQUHW-UHFFFAOYSA-N 0.000 description 1
- ZWJANXHNJZEDMH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C#N)=NC=2N=C1N1CCCC(N)C1 ZWJANXHNJZEDMH-UHFFFAOYSA-N 0.000 description 1
- NZGQGUPAFCAOJA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C=NC=2N=C1N1CCCC(N)C1 NZGQGUPAFCAOJA-UHFFFAOYSA-N 0.000 description 1
- UQSWQJJPOGGQQO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-phenacylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC=CC=1)C=N2 UQSWQJJPOGGQQO-UHFFFAOYSA-N 0.000 description 1
- HXWQZVWDSUEFRU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(3-methylbut-2-enyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=C(C)C)C=1NCC1=CC=CC=C1 HXWQZVWDSUEFRU-UHFFFAOYSA-N 0.000 description 1
- UWQCGERNMURRHS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(3-methylbutyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC(C)C)C=1NCC1=CC=CC=C1 UWQCGERNMURRHS-UHFFFAOYSA-N 0.000 description 1
- ZQGWISQRKYCGOP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(cyclopropylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CC1)C(NCC=1C=CC=CC=1)=N2 ZQGWISQRKYCGOP-UHFFFAOYSA-N 0.000 description 1
- VIZCBMNLYXPJMN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(2-fluorophenyl)methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C(=CC=CC=1)F)C(NCC=1C=CC=CC=1)=N2 VIZCBMNLYXPJMN-UHFFFAOYSA-N 0.000 description 1
- QXWYUIGSGHARFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-butylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC)C=1NCC1=CC=CC=C1 QXWYUIGSGHARFG-UHFFFAOYSA-N 0.000 description 1
- COWMBNCWTNXKOG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-ethylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC)C=1NCC1=CC=CC=C1 COWMBNCWTNXKOG-UHFFFAOYSA-N 0.000 description 1
- UFPCFFWFBRMRMN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-hexylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCCC)C=1NCC1=CC=CC=C1 UFPCFFWFBRMRMN-UHFFFAOYSA-N 0.000 description 1
- LSEPJOQVNUUIFD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-pentylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCC)C=1NCC1=CC=CC=C1 LSEPJOQVNUUIFD-UHFFFAOYSA-N 0.000 description 1
- JJDZCAIGGHSXLP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-propylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C=1NCC1=CC=CC=C1 JJDZCAIGGHSXLP-UHFFFAOYSA-N 0.000 description 1
- QRQTZCLBERGDRY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCCC1 QRQTZCLBERGDRY-UHFFFAOYSA-N 0.000 description 1
- ZQTVLUMISDWHHA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCCC1 ZQTVLUMISDWHHA-UHFFFAOYSA-N 0.000 description 1
- DDTSUZKXIYLGRL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(dimethylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)C)=NC=2N=C1N1CCCC(N)C1 DDTSUZKXIYLGRL-UHFFFAOYSA-N 0.000 description 1
- LYJDRLPVJWTZKU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methylamino]-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(F)C=C1 LYJDRLPVJWTZKU-UHFFFAOYSA-N 0.000 description 1
- GPQOSSCLFVBKQA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-benzylsulfanyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1SCC1=CC=CC=C1 GPQOSSCLFVBKQA-UHFFFAOYSA-N 0.000 description 1
- UFVDMGHRYOTQOX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-benzylsulfanyl-3h-purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N=C(SCC=1C=CC=CC=1)N2 UFVDMGHRYOTQOX-UHFFFAOYSA-N 0.000 description 1
- LIIVCHKCCYQBAO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-1-(2-phenylethyl)purin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CCC=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 LIIVCHKCCYQBAO-UHFFFAOYSA-N 0.000 description 1
- JKKVVPOLSIWJIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-1-phenacylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 JKKVVPOLSIWJIF-UHFFFAOYSA-N 0.000 description 1
- WSCQYLYICZOBJS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-3h-purin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)NC(SC)=NC=2N=C1N1CCCC(N)C1 WSCQYLYICZOBJS-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100460776 Arabidopsis thaliana NPY2 gene Proteins 0.000 description 1
- 101100460788 Arabidopsis thaliana NPY5 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- LQDFIFKEAZAXRF-UHFFFAOYSA-N C(C1=CC=CC=C1)N(C(O)=NOC#N)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)N(C(O)=NOC#N)C1=CC=CC=C1 LQDFIFKEAZAXRF-UHFFFAOYSA-N 0.000 description 1
- 0 CC(N(*)C1=O)=Nc2c1[n](*)c(*)n2 Chemical compound CC(N(*)C1=O)=Nc2c1[n](*)c(*)n2 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 description 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 206010020648 Hyperkeratoses Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 101150111774 NPY5R gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RKFJLAMKBRRYJG-UHFFFAOYSA-M [Br-].[Mg+]CCC1=CC=CC=C1 Chemical compound [Br-].[Mg+]CCC1=CC=CC=C1 RKFJLAMKBRRYJG-UHFFFAOYSA-M 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JRVPNEOAXCUHNN-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 JRVPNEOAXCUHNN-UHFFFAOYSA-N 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- JKNKNWJNCOJPLI-UHFFFAOYSA-N o-phthalaldehydic acid Chemical compound C1=CC=C2C(O)OC(=O)C2=C1 JKNKNWJNCOJPLI-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- JWEQRJSCTFBRSI-PCLIKHOPSA-N rboxylate Chemical compound COC(=O)C1C(N2C3=O)C4=CC=CC=C4OC1(C)N=C2S\C3=C\C(C=1)=CC=C(OC)C=1COC1=CC=CC=C1C JWEQRJSCTFBRSI-PCLIKHOPSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 1
- KRRBFUJMQBDDPR-UHFFFAOYSA-N tetrabutylazanium;cyanide Chemical compound N#[C-].CCCC[N+](CCCC)(CCCC)CCCC KRRBFUJMQBDDPR-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10238477A DE10238477A1 (de) | 2002-08-22 | 2002-08-22 | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238477.0 | 2002-08-22 | ||
| PCT/EP2003/009100 WO2004018469A1 (de) | 2002-08-22 | 2003-08-16 | Neue purinderivate, deren herstelllung und deren verwendung als arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2496211A1 true CA2496211A1 (en) | 2004-03-04 |
Family
ID=31197237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002496211A Abandoned CA2496211A1 (en) | 2002-08-22 | 2003-08-16 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1532150B1 (https=) |
| JP (1) | JP2006502144A (https=) |
| AT (1) | ATE398128T1 (https=) |
| AU (1) | AU2003258621A1 (https=) |
| CA (1) | CA2496211A1 (https=) |
| DE (2) | DE10238477A1 (https=) |
| ES (1) | ES2308017T3 (https=) |
| WO (1) | WO2004018469A1 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CA2518465A1 (en) * | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| JP4797021B2 (ja) * | 2004-10-01 | 2011-10-19 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| AU2005309606B2 (en) * | 2004-11-29 | 2011-01-06 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP5075125B2 (ja) * | 2005-08-26 | 2012-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防用ジペプチジルペプチダーゼｉｖ阻害剤としての縮合アミノピペリジン |
| MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CA2631737C (en) * | 2005-12-14 | 2013-03-26 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| CA2724715A1 (en) | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| NZ604091A (en) | 2008-08-15 | 2014-08-29 | Boehringer Ingelheim Int | Purin derivatives for use in the treatment of fab-related diseases |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| NZ598170A (en) | 2009-10-02 | 2014-06-27 | Boehringer Ingelheim Int | Pharmaceutical compositions comprising bi-1356 and metformin |
| EP2499142B1 (en) * | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| CA2795513A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| AR082091A1 (es) | 2010-05-05 | 2012-11-14 | Boehringer Ingelheim Int | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2729468A4 (en) * | 2011-07-05 | 2015-03-18 | Merck Sharp & Dohme | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN103130819B (zh) * | 2011-12-01 | 2016-01-20 | 中国科学院上海药物研究所 | 噻吩[3,2-d]并嘧啶-4-酮类化合物、其制备方法、药物组合物及用途 |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US20150246117A1 (en) | 2012-09-24 | 2015-09-03 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP3744327A1 (en) | 2013-03-15 | 2020-12-02 | Boehringer Ingelheim International GmbH | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| RU2020133727A (ru) * | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| EP4608388A1 (en) | 2022-10-25 | 2025-09-03 | Starrock Pharma Inc. | Combinatorial, and rotational combinatorial therapies for obesity and other diseases |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
| AU1688599A (en) * | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| AU2001268958B2 (en) * | 2000-07-04 | 2006-03-09 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
-
2002
- 2002-08-22 DE DE10238477A patent/DE10238477A1/de not_active Withdrawn
-
2003
- 2003-08-16 AU AU2003258621A patent/AU2003258621A1/en not_active Abandoned
- 2003-08-16 DE DE50309979T patent/DE50309979D1/de not_active Expired - Lifetime
- 2003-08-16 WO PCT/EP2003/009100 patent/WO2004018469A1/de not_active Ceased
- 2003-08-16 CA CA002496211A patent/CA2496211A1/en not_active Abandoned
- 2003-08-16 AT AT03792343T patent/ATE398128T1/de active
- 2003-08-16 JP JP2004530172A patent/JP2006502144A/ja active Pending
- 2003-08-16 EP EP03792343A patent/EP1532150B1/de not_active Expired - Lifetime
- 2003-08-16 ES ES03792343T patent/ES2308017T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2308017T3 (es) | 2008-12-01 |
| EP1532150A1 (de) | 2005-05-25 |
| DE10238477A1 (de) | 2004-03-04 |
| EP1532150B1 (de) | 2008-06-11 |
| WO2004018469A1 (de) | 2004-03-04 |
| DE50309979D1 (de) | 2008-07-24 |
| JP2006502144A (ja) | 2006-01-19 |
| ATE398128T1 (de) | 2008-07-15 |
| AU2003258621A1 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7569574B2 (en) | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CA2496211A1 (en) | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| US7838529B2 (en) | Xanthine derivates, their preparation and their use in pharmaceutical compositions | |
| US7393847B2 (en) | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | |
| US7495003B2 (en) | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | |
| CA2496325A1 (en) | Phenacyl xanthine derivatives as dpp-iv inhibitor | |
| US7560450B2 (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CA2548323C (en) | Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| US7470716B2 (en) | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | |
| US7482337B2 (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| US7566707B2 (en) | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| US7179809B2 (en) | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions | |
| CA2505389C (en) | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CA2576294A1 (en) | Novel 3-methyl-7-butinyl-xanthines, production thereof, and use thereof as medicaments | |
| CA2561210A1 (en) | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments | |
| CA2543074A1 (en) | Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus | |
| CA2556064A1 (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof, and the use of the same as medicaments | |
| CA2544480A1 (en) | Novel 8-(piperazine-1-yl)- and 8-([1,4]diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug | |
| CA2529729A1 (en) | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | |
| CA2660197A1 (en) | Pyrrolo[3,2-d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus | |
| NZ548901A (en) | 8-[3-Amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor | |
| CA2559444A1 (en) | Imidazopyridazine diones, the production thereof, and the use of the same as a medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |